HBV Cure 2017 – Presentations

   Session 1: Clinical Update on HBV Cure
 Lampertico, Pietro 2013TAF – The latest update, which questions remain to be answered?
Pietro Lampertico
, MD, PhD -University of Milan, Milan, Italy
 Zoulim, Fabien 2011_120Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement
Fabien Zoulim
, MD, PhD - INSERM, Paris, France

Is immunomodulation really needed to cure HBV?
Harry Janssen,
MD, PhD - Toronto Centre for Liver Disease, Toronto, Canada

   Session 2: New biomarkers: how will they help us?
 How to use new virological biomarkers to assess HBV cure: quantitative HBsAg, HBcrAg, HBV-RNA (not yet available)
Florian Bömmel,
MD - University of Leipzig, Leipzig, Germany

 Lauer, Georg 2017To look inside or outside of the liver for evidence of HBV cure? (not available)
Georg Lauer, MD, PhD - Massachusetts General Hospital Boston, MA, USA

   Session 3: Latest update on New Treatment modalities - Immunologic response
 How does HBV interact with the immune system
Mala Maini
, MD, PhD - University College London, London, United Kingdom

 Gehring, Adam 2014Innate Immunity : TLR, RIG-I, STING and potential others
Adam Gehring
, PhD - University of Toronto, Toronto, Canada

 Boonstra, Andre 2017Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others
Andre Boonstra,
PhD - Erasmus Medical Center, Rotterdam, the Netherlands

   Session 4: Latest update on New Treatment modalities - Virologic update
 Urban, Stephen, 2016 120x160Entry inhibition
Stefan Urban, 
PhD - Heidelberg University, Heidelberg, Germany

 Gaggar, Anuj 2017CCC – DNA inhibition
Anuj Gaggar
MD, PhD - Gilead Sciences, Foster City, USA

 Symonds, William 2017RNA interference
Bill Symonds,
PharmD - Arbutus, Burnaby, Canada

  Lam, Angela 2017Capsid inhibition (not available)
Angela Lam, PhD - Janssen, USA
 Tavis, John 2017HBV Ribonuclease H
John Tavis
, PhD - Saint Louis University School of Medicine, Saint Louis, MO, USA


Stephan Locarnini, BSC, PhD, MBBS, FRC

Other virological mechanisms
Stephen Locarnini, BSc, PhD, MBBS, FRCP - Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia

   Session 5: From the science to the clinic

Marion Peters, MD

Is personalized therapy needed to achieve success? (not available)
Marion PetersMD - University of California San Francisco, San Francisco, CA, USA

 Feld, Jordan 2016 120Combination therapy how to navigate in a minefield of efficacy and toxicity?
Jordan Feld
, MD - Toronto Centre for Liver Disease, Toronto, Canada
  Chan, Henry 2017 120Innovative trial design
Henry Lik Yuen Chan
, MD - Chinese University of Hong Kong, Hong Kong